$MBRX News

Last published 15h ago

15h agoMBRXMoleculin Secures Australian Patent for Annamycin Formulation TechnologyGlobeNewswirePatent strengthens intellectual property protection for preparation of preliposomal Annamycin lyophilizate
2d agoMBRXPreclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with ImmunotherapiesGlobeNewswireInhibition of CD8+ T cells shortens survival in Annamycin-treated mice, demonstrating the immune system is a functional contributor to Annamycin’s antitumor activity, not a bystander
1w agoMBRXMoleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual MeetingGlobeNewswireFirst interim results from pivotal Phase 2/3 trial highlight encouraging remission rates in patients with relapsed or refractory AML HOUSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (NASDAQ:MBRX)
1w agoMBRXMoleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027GlobeNewswireMilestone underscores execution of pivotal Phase 2/3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML) Fully treated, randomized, double-blind n=90 Part A
3w agoMBRXMoleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE TrialGlobeNewswireAccess the Moleculin CEO Corner here HOUSTON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (NASDAQ:MBRX) ("Moleculin" or the "Company") today announced that it has released the next
3w agoMBRXMoleculin Announces Reverse Stock SplitGlobeNewswireHOUSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that it filed an amendment to its amended and restated certificate of
1mo agoMBRXMoleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth SummitGlobeNewswireHOUSTON, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (NASDAQ:MBRX) ("Moleculin" or the "Company") today announced that it will present at the upcoming 2026 Maxim Growth Summit in New
1mo agoMBRXMoleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific MeetingsGlobeNewswirePresentations examine where Annamycin concentrates in the body, how it targets topoisomerase II, and its antitumor activity in pancreatic cancer HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.
2mo agoMBRXMoleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand ConferenceGlobeNewswire- Video webcast now available here HOUSTON, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that it participated in the Virtual
2mo agoAIM AKTX CNSP DARE+5JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOsACCESS NewswireNine CEOs. Nine investment stories. 60 seconds each to answer the question that matters most to investors: Why now?On-demand video series gives investors rapid access to company leadership, recent milestones, upcoming
3mo agoMBRXMoleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE TrialGlobeNewswirePositive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AMLMIRACLE trial advancing toward planned 90-patient enrollment milestone in September 2026 with the
3mo agoMBRXMoleculin Announces Pricing of $9.3 Million Public OfferingGlobeNewswireHOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced the pricing of a best-efforts public offering of an aggregate of
3mo agoMBRXMoleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed PatientsGlobeNewswirePrior venetoclax failure — a setting in which published salvage remission rates are approximately 13% and median survival approximately 2.4 months — shows no adverse impact on blinded composite remission rates as
4mo agoMBRXMBRX_Why One Cycle Matters_07.06.26 - JTC TEAMEarnings Call TranscriptsWe do need to keep in mind that this is after only a single cycle of treatment. Based on the most commonly cited historical trials, you'd normally expect to see high DAC monotherapy, that's our control arm, deliver a 17
4mo agoMBRXMBRX_WTM_P3Data_07.06.26 - MBRXEarnings Call TranscriptsWe've been working toward this moment for years now and we finally have our first look at phase 3 pivotal data based on the first 45 patients enrolled and it looks fantastic. The Anamycin test arms outperformed control b
4mo agoMBRXMBRX_Competitive Landscape - JTC TEAMEarnings Call TranscriptsWe know that one thing on the minds of many hematology oncologists is the continued effort to utilize targeted therapies in AML and many of them have asked us how we see the competitive landscape playing out as we begin
4mo agoMBRXMoleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" SegmentGlobeNewswireAccess the segment here HOUSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief
4mo agoMBRXMBRX_Moleculin Opportunity - JTC TEAMEarnings Call TranscriptsWe do believe that all this new data makes a very strong case for Anamycin's eventual approval and for it to have commercial potential measured in the billions. Sooner or later though, the conversation always comes aroun
4mo agoMBRXMBRX_Market Potential_07.06.26 - JTC TEAMEarnings Call TranscriptsWe do think that the new phase 3 data clearly raises confidence in the likelihood that anamycin will be approved for use in AML. But look, a reasonable follow-on question is whether that will translate into significant c
4mo agoMBRXMBRX_45-Patient Interim Results - JTC TEAMEarnings Call TranscriptsWe've been working toward this moment for years now, and we finally have our first look at phase three pivotal data based on the first 45 patients enrolled, and it looks fantastic. The Anamycin test arms outperformed con
4mo agoMBRXMBRX_Annamycin vs. Current Anthracyclines_07.06.26 - JTC TEAMEarnings Call TranscriptsWell, that's where we believe anamycin's improved safety profile really stands out. Anamycin is designed to be non-cardiotoxic, and the data to date, reviewed independently, showed no evidence of cardiotoxicity. And that
4mo agoMBRXMBRX_Venetoclax Patients - JTC TEAMEarnings Call TranscriptsWe always have to be careful when discussing pooled data because there are minor differences in the protocol between the trials. But when you combine this interim phase three data with the phase two data we already had,
4mo agoMBRXMoleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than ControlGlobeNewswireBoth Annamycin dose arms outperformed control on the primary endpoint of complete remission (CR): 43% and 36% versus 12% — reported on a full intent-to-treat (ITT) basis with no patient exclusionsComposite complete
5mo agoMBRXIndependent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AMLGlobeNewswireSurveyed oncologists reported high likelihood to prescribe (6 of 7), citing deep remissions, transplant-bridging potential, biomarker-agnostic use and reduced cardiotoxicity as key drivers Parallel survey of payers
5mo agoMBRXMoleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor "What This Means" SegmentGlobeNewswire- Access the segment here HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive Officer of
5mo agoMBRXMoleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline LimitsGlobeNewswireIndependent Cleveland Clinic Cardiac Review Supports Potential Best-in-Class Safety Profile as MIRACLE Phase 2b/3 Trial Advances HOUSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX)
5mo agoMBRXMoleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for AnnamycinGlobeNewswireHOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that an abstract featuring pooled cardiac safety data for its lead drug candidate
6mo agoMBRXMoleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE TrialGlobeNewswireEarly blinded results show 40% composite complete remission rate across difficult-to-treat AML patient population in MIRACLE Trial First interim unblinding expected in June 2026 following 45 subject enrollment milestone
6mo agoMBRXMoleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical BenchmarksGlobeNewswirePreliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~67% improvement vs. standard of careFirst 45-subject data unblinding expected before June 30, 2026Program targets
6mo agoMBRXIndependent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline LimitsGlobeNewswirePooled analysis of 90 subjects across 5 trials shows stable mean ejection fraction and no clinically significant left ventricular dysfunction Data demonstrates Annamycin addresses the principal barrier to anthracycline
6mo agoMBRXMoleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of AnnamycinGlobeNewswireSolid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data Release HOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"),
6mo agoMBRXMoleculin's Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026GlobeNewswireNon-cardiotoxic anthracycline demonstrates activity where traditional chemotherapies have historically failed, supporting potential expansion of Annamycin into a major unmet-need indication Significant tumor volume
6mo agoMBRXMoleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual MeetingGlobeNewswireHOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that an abstract highlighting data on its lead drug candidate, annamycin, has been
7mo agoMBRXMoleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic ProfileGlobeNewswireAccess the Moleculin CEO Corner here HOUSTON, April 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced it has released the next segment on its CEO
7mo agoIBRX FATE GUTS MBRXScalable Biotech Manufacturing Unlocks a $14B MarketPR NewswireUSANewsGroup.com News Commentary — The global cell therapy manufacturing market is hitting a pivotal inflection point. It's projected to surpass $7...
7mo agoMBRXMoleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data ReadoutGlobeNewswireFirst Interim Unblinding of Pivotal AML Trial Now Imminent — Potentially the Most Important Data Moment in Company HistoryEarly Blinded Results Show 40% Remission Rate Across Difficult-to-Treat Patient
8mo agoMBRXMoleculin Announces Exercise of Warrants for $8.3 Million Gross ProceedsGlobeNewswireHOUSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced it has entered into agreements with certain holders of its existing warrants for the
8mo agoMBRXMoleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)GlobeNewswirePreliminary blinded CR rate showed 67% improvement over historical cytarabine response Roughly 35% of the subjects treated to date represent ventoclax regimen failuresFirst 45 subjects treated on track for Q1 2026
8mo agoMBRXMoleculin Announces Notice of Allowance for Japanese Patent Covering AnnamycinGlobeNewswireHOUSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that the Japan Patent Office (JPO) has issued a notice of allowance for Patent
9mo agoMBRXMoleculin Launches CEO Corner Platform to Share Strategic InsightsGlobeNewswireCEO Corner segments intended to provide added perspective to press releases, clinical trial developments and pipeline progress Provides interested parties with the ability to connect with the Company by submitting
9mo agoAIM AKTX BULL DCOY+2JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026ACCESS NewswireRegister for the two-day virtual event hereFRENCHTOWN, NJ / ACCESS Newswire / February 9, 2026 / JTC Team , a fully integrated corporate communications and investor relations firm, today announced its companies
9mo agoMBRXMoleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull FinancialGlobeNewswire– Live video webcast on Wednesday, February 11th at 1:20 PM EST HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that it will
10mo agoMBRXMoleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 SubjectsGlobeNewswire– Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials – This next-generation anthracycline demonstrates safety and promising early activity in treating multiple oncology
10mo agoMBRXMoleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical ProgramsGlobeNewswire– First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and brain cancer trials HOUSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Moleculin
11mo agoMBRXMoleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain TumorsGlobeNewswireEmory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children's Healthcare of AtlantaResults demonstrated WP1066 induces anti-tumor immune responses and were
11mo agoMBRXMoleculin Announces Exercise of Warrants for $6.8 Million Gross ProceedsGlobeNewswireHOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat
11mo agoMBRXMoleculin Announces Completion of Treatment for the 45 Patients in Pivotal "MIRACLE" Phase 3 AML Trial on Pace for Q1 2026GlobeNewswireContinues to drive enrollment with increase to 78% now consentedBlinded response activity tracking within expected range Consented subjects now across seven countries supporting the expansion of the MIRACLE trial
11mo agoMBRXMoleculin Announces New Annamycin Collaboration in Brain TumorsGlobeNewswireInvestigator-Initiated Preclinical studies at CIC biomaGUNE aimed at combatting Glioblastoma Multiforme Research will evaluate effects of intra-arterial delivery of Annamycin HOUSTON, Dec. 08, 2025 (GLOBE NEWSWIRE)
11mo agoMBRXMoleculin to Participate in the Virtual Investor Closing Bell SeriesGlobeNewswireLive video webcast with Walter Klemp, Chairman and Chief Executive Officer, on Tuesday, December 2nd at 4:00 PM ET HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the
11mo agoMBRXMoleculin Announces Reverse Stock SplitGlobeNewswireHOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that it filed an amendment to its amended and restated certificate of incorporation with